Story perspectives

States Push for GLP-1 Drug Coverage Amid Challenges

10/29/2025

24 4

Summary

Story summary

Access to GLP-1 obesity medications such as Wegovy and Zepbound remains limited in the United States as many insurers do not cover them, leaving patients with high out-of-pocket costs.
CVS Caremark has favored Wegovy over Zepbound, drawing dissatisfaction from doctors and patients.
North Dakota is mandating insurance coverage for GLP-1 drugs.
Other states have faced vetoes and budget constraints in their legislative efforts, underscoring the ongoing challenges to broaden access.

1 of 1

Story summary

Access to GLP-1 obesity medications such as Wegovy and Zepbound remains limited in the United States as many insurers do not cover them, leaving patients with high out-of-pocket costs.
CVS Caremark has favored Wegovy over Zepbound, drawing dissatisfaction from doctors and patients.
North Dakota is mandating insurance coverage for GLP-1 drugs.
Other states have faced vetoes and budget constraints in their legislative efforts, underscoring the ongoing challenges to broaden access.